Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate

Article

Abstract: Objectives Raloxifene is approved for the treatment and prevention of postmenopausal osteoporosis. P

Palabras claves:

Hot Flushes, OSTEOPOROSIS, Postmenopausal women, Raloxifene, Selective estrogen receptor modulators

Autores:

Almeida M.J., Gustavo J. Gómez, Kayath M.J., Lucia F. Farias M., Luebbert H., Mönnig E., Nickelsen T., Palacios S., Quail D.C., Turbi C., Yabur J.A.

Fuentes:

scopus